ClinicalTrials.gg
TerminatedNCT02474407Updated Oct 16, 2018Results posted

Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)

A Phase 2 interventional study of diazepam nasal spray and diazepam rectal gel in Refractory Epilepsy, sponsored by Acorda Therapeutics. Terminated at 22 sites in United States. Open to participants aged 12 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-10-16.

Sponsored by Acorda Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
12 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 78 studies in Drug Resistant Epilepsy with a site in United States — 29 open to participants now, 34 under way, 2 of them phase 3. Drug Resistant Epilepsy · United States.

Enrollment
19th of 67
78 · median 27
Started
2015
with 3 others
Phase 2
9 of 78
1 open now
Registered
12th of 78
by date

Among the 78 studies in Drug Resistant Epilepsy with a site in United States, this one is the 19th largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2015, is one of 9 in phase 2, and was the 12th registered.

Drug Resistant Epilepsy

257 studies on the registry are indexed under Drug Resistant Epilepsy; 108 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

29 of the 78 studies in Drug Resistant Epilepsy with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Drug Resistant Epilepsy studies recruiting now, 26 (39%) set no upper age limit and 39 (59%) stop at 75 or younger; 25 take children under 18; 6 take healthy volunteers.

This study: 12 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies in Drug Resistant Epilepsy with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, open-label, crossover, pharmacokinetic, bio-availability study involving adolescents and adults with refractory (drug-resistant) epilepsy. Cohort 1 comprises the subjects used to determine the relative bioavailability of DZNS versus DRG (Diastat)

Read the detailed description

To determine the bioavailability of diazepam nasal spray versus diazepam rectal gel (Diastat®) under conditions of use in adolescent and adult persons with epilepsy (PWE) meeting the definition of refractory epilepsy.

03

Conditions studied

  • Refractory Epilepsy

Keywords

  • Seizures
  • Epilepsy
04

Who can participate

Ages eligible
12 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of epilepsy
  • Body weight 26 to 111 kilogram (kg) inclusive
  • Other inclusion criteria apply

Exclusion criteria

Exclusion Criteria:

  • Male or female subject who is not surgically sterile or female subject who is less than 2 years , and does not agree to use a highly effective method during the study and up to 3 months after the last dose of product
  • Female subject who is pregnant, breastfeeding, or planning to become pregnant
  • Presence or history of any abnormality or illness that may affect the absorption, distribution, metabolism or elimination of diazepam
  • Other exclusion criteria apply
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    diazepam nasal spray (DZNS)

    One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.

    Drug: diazepam nasal spray

  • Active comparator
    diazepam rectal gel (DRG)

    A single rectal dose of diazepam will be administered to subjects according to the Diastat prescribing information.

    Drug: diazepam rectal gel

Interventions

06

What researchers measure

Primary outcomes

  1. AUC 0-24h

    Relative bioavailability based on area under time plasma concentration curve.

    Time frame: 24 hours

  2. Cmax

    Relative bioavailability based on maximum observed plasma concentration.

    Time frame: 24 hours

Secondary outcomes

  1. Focused Nasal Exam (Part A)

    A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded "none" to Grade 4 "septal perforation." Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)

    Time frame: pre-dose (day 1) up to 24 hours post-dose

  2. Focused Nasal Exam (Part B)

    A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)

    Time frame: pre-dose (day 1) up to 24 hours post-dose

  3. Smell Identification Test (SIT)

    The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different "scratch and sniff" strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender.

    Time frame: day 1 up to day 31

  4. Taste Change Questionnaire

    Questionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented.

    Time frame: Up to 24 hours

07

Results

Posted Oct 16, 2018

Participant flow

This is a randomized crossover study with 78 subjects total.

First Intervention (14 Days)
Participant flow — First Intervention (14 Days)
MilestoneSingle Dose of Diazapam Nasal Spray (DZNS)Single Dose of Diazapam Rectal Gel (DRG)
Started3939
Completed3939
Not completed00
Washout (14 Days)
Participant flow — Washout (14 Days)
MilestoneSingle Dose of Diazapam Nasal Spray (DZNS)Single Dose of Diazapam Rectal Gel (DRG)
Started3939
Completed3939
Not completed00
Second Intervention (14 Days)
Participant flow — Second Intervention (14 Days)
MilestoneSingle Dose of Diazapam Nasal Spray (DZNS)Single Dose of Diazapam Rectal Gel (DRG)
Started3939
Completed3939
Not completed00

Outcome measures

PrimaryAUC 0-24h

Relative bioavailability based on area under time plasma concentration curve.

Time frame:
24 hours
Reported as:
Mean · ng*h/mL
AUC 0-24h
ng*h/mLSingle Dose of Diazapam Nasal Spray (DZNS)Single Dose of Diazapam Rectal Gel (DRG)
AUC 0-24h1357.7 ± 802.782117.9 ± 996.27
PrimaryCmax

Relative bioavailability based on maximum observed plasma concentration.

Time frame:
24 hours
Reported as:
Mean · ng/mL
Cmax
ng/mLSingle Dose of Diazapam Nasal Spray (DZNS)Single Dose of Diazapam Rectal Gel (DRG)
Cmax157.0 ± 120.15309.3 ± 137.95
SecondaryFocused Nasal Exam (Part A)

A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Nasal irritation will be graded "none" to Grade 4 "septal perforation." Grade 1a= focal irritation, Grade 1b= superficial mucosal erosion, Grade 2= moderate mucosal erosion, Grade 3= ulceration, Grade 4= septal perforation. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)

Time frame:
pre-dose (day 1) up to 24 hours post-dose
Reported as:
Count of participants · Participants
Focused Nasal Exam (Part A)
ParticipantsDZNS - At 24 Hours Post-Dose - NONEDZNS - At 24 Hours Post-Dose - Grade 1aDZNS - At 24 Hours Post-Dose - Grade 1bDZNS - At 24 Hours Post-Dose - Grade 2DZNS - At 24 Hours Post-Dose - Grade 3DZNS - At 24 Hours Post-Dose - Grade 4DZNS - At 24 Hours Post-Dose - Missing
Nasal Irritation at Baseline - NONE64601000
Grade 1a1300000
Grade 1b0020000
Grade 30000100
SecondaryFocused Nasal Exam (Part B)

A focused nasal exam was completed by the Investigator in the treatment period(s) when diazepam nasal spray was administered, based on a visual inspection of the nasal mucosa. Focused Nasal Examination Part B - will show nasal mucosal symptoms that will be rated for severity will include discharge, mucosal edema, crusting, erythema, and epistaxis. This exam may be conducted within a 5 minute window after the specified time point. Between the 12 and 24 h time points, the exam was should be repeated every 4 hours as needed to follow any residual symptoms to resolution and the time of resolution should be documented. (Categories with no data were omitted)

Time frame:
pre-dose (day 1) up to 24 hours post-dose
Reported as:
Count of participants · Participants
Focused Nasal Exam (Part B)
ParticipantsDZNS - At 24 Hours Post-Dose NoneDZNS - At 24 Hours Post-Dose MildDZNS - At 24 Hours Post-Dose ModerateDZNS - At 24 Hours Post-Dose SevereDZNS - At 24 Hours Post-Dose Missing
At Baseline: Mucosal Edema-None703000
Mucosal Edema - Mild13000
Mucosal Edema - Moderate01000
At Baseline: Nasal Discharge - None677100
Nasal Discharge - Mild11000
Nasal Discharge - Moderate01000
At Baseline: Mucosal Erythema - None676000
Mucosal Edrythema - Mild05000
At Baseline: Mucosal Bleeding/Epistaxis - None761000
Mucosal Bleeding/Epistaxis - Mild10000
At Baseline: Crusting of Mucosa - None771000
SecondarySmell Identification Test (SIT)

The SIT is a validated test of smell identification which scores patients into different levels of olfactory function normalized by age and gender, however it had not been validated for use in PWE. The Smell Identification Test (SIT) is a 40-item multiple-choice standardized test. The test can be self-administered and consists of four 10-page booklets with a different "scratch and sniff" strip on each page. A scratch with a pencil releases the scent from the strip, and the subject is then asked to match the scent to one of four choices on the page. An answer must be selected for each of the 40 items, even when the subject cannot detect a smell. The total score (i.e., number of correct answers, range: 0-40) can be compared against normative data collected from approximately 4000 normal individuals between ages 4 to 99 to determine the subject's percentile rank of olfactory dysfunction corrected for age and gender.

Time frame:
day 1 up to day 31
Reported as:
Count of participants · Participants
Smell Identification Test (SIT)
ParticipantsAt Follow-Up Visit - NormosmiaAt Follow-Up Visit - Mild MicrosmiaAt Follow-Up Visit - Moderate MicrosmiaAt Follow-Up Visit - Severe MicrosmiaAt Follow-Up Visit - AnosmiaAt Follow-Up Visit - Probable MalingeringAt Follow-Up Visit - Missing
At BASELINE: Normosmia191000001
Mild Microsmia21051000
Moderate Microsmia2336100
Severe Microsmia0114100
Anosmia0002301
Probable Malingering0000000
Missing0000002
SecondaryTaste Change Questionnaire

Questionnaire given to safety population in Cohort 1 for reporting taste change during the study. If the subject spontaneously reports an experience of taste change associated with diazepam nasal spray dosing, it will be evaluated qualitatively by the research staff using a taste change questionnaire. The subject will be asked to describe the type, intensity, and duration of the change in taste at multiple scheduled time points after dosing. Between the 12 and 24 h time points, the questionnaire should be repeated every 4 hours as needed to follow any residual symptoms to resolution, and time of resolution should be documented.

Time frame:
Up to 24 hours
Reported as:
Mean · units on a scale
Taste Change Questionnaire
units on a scaleTaste Change by Intensity in Cohort 1
5 mins Post-Dose6.5 ± 3.57
15 mins Post-Dose4.6 ± 3.09
30 mins Post Dose2.8 ± 2.75
1 hr Post Dose1.0 ± 1.45
2 hrs Post-Dose0.3 ± 0.48
4 hrs Post-Dose0.1 ± 0.36
8 hrs Post-Dose0.0 ± 0.0
12 hrs Post-Dose0.0 ± 0.0
24 hrs Post-Dose0.0 ± 0.0

Adverse events

Collected over 31 Days. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diazepam Nasal Spray0/78 (0%)0/78 (0%)60/78 (76.9%)
Diazepam Rectal Gel0/78 (0%)0/78 (0%)20/78 (25.6%)
Most frequent other events
Showing 10 of 37
Most frequent other events
EventDiazepam Nasal SprayDiazepam Rectal Gel
Nasal DiscomfortGeneral disorders30/783/78
DysgeusiaGeneral disorders25/780/78
Lacrimation IncreasedGeneral disorders22/780/78
Nasal Mucosal DisorderGeneral disorders10/782/78
RhinorrheaGeneral disorders10/781/78
Throat irritationGeneral disorders9/780/78
Edema MucosalGeneral disorders8/781/78
SomnolenceNervous system disorders4/785/78
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders4/780/78
RhinalgiaRespiratory, thoracic and mediastinal disorders4/780/78

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Participants
<=18 years2
Between 18 and 65 years75
>=65 years1
Age, Continuous
Age, Continuous(years)All Participants
Mean41.4 ± 13.52
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female51
Male27
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino5
Not Hispanic or Latino73
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native1
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American13
White57
More than one race0
Unknown or Not Reported6
Region of Enrollment
Region of Enrollment(Participants)All Participants
United States78
08

Study locations

22 sites
  • Acorda Site #115
    Little Rock, Arkansas 72205, United States
  • Acorda Site #127
    Washington, District of Columbia 20010, United States
  • Acorda Site #101
    Tampa, Florida 33606, United States
  • Acorda Site #125
    Honolulu, Hawaii 96817, United States
  • Acorda Site #104
    Lexington, Kentucky 40513, United States
  • Acorda Site #111
    Baltimore, Maryland 21201, United States
  • Acorda Site #102
    Bethesda, Maryland 20817, United States
  • Acorda Site #110
    Ann Arbor, Michigan 48105, United States
  • Acorda Site #117
    Jackson, Mississippi 39216, United States
  • Acorda Site #112
    Saint Louis, Missouri 63131, United States
  • Acorda Site #128
    Edison, New Jersey 08818, United States
  • Acorda Site #121
    Hackensack, New Jersey 07601, United States
  • Acorda Site #123
    Amherst, New York 14226, United States
  • Acorda Site #119
    Rochester, New York 14642, United States
  • Acorda Site #132
    Chapel Hill, North Carolina 27599, United States
  • Acorda Site #114
    Portland, Oregon 97239, United States
  • Acorda Site #116
    Philadelphia, Pennsylvania 19104, United States
  • Acorda Site #105
    Philadelphia, Pennsylvania 19107, United States
  • Acorda Site #130
    Memphis, Tennessee 38105, United States
  • Acorda Site #103
    Bellaire, Texas 77401, United States
  • Acorda Site #122
    Dallas, Texas 75251, United States
  • Acorda Site #108
    Houston, Texas 77004, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of May 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2015
First posted
Jun 17, 2015
Start
Jun 2015
Primary completionActual
May 2016
CompletionActual
Jul 2016
Results first posted
Oct 16, 2018
Last update
Oct 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02474407
Responsible party
Sponsor
First posted
Jun 17, 2015
Start date
Jun 2015
Primary completion
May 2016
Completion
Jul 2016
Results posted
Oct 16, 2018
Last update
Oct 16, 2018

Study contacts

Lee Min Jae
study director · SK Biopharmaceuticals Co, Ltd

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion